Pharmaceutical products
Original notice title
Italy-Naples: Pharmaceutical products
Opportunity Score
Why this score?
Opportunity
70 / 100
Complexity
65 / 100
Risk factors
Only the notice and XML data are available; full procurement documents (specifications, contract terms, qualification c...
The high estimated value (€20 billion) is likely to attract many bidders, including large pharmaceutical companies, mak...
Restricted procedure — pre-qualification required
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- SOCIETA' REGIONALE PER LA SANITA' (SO.RE.SA. S.P.A.)
- Country
- Italy
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Dec 06, 2028
- Estimated value
- EUR 20000M
Overview
Strong opportunityKey Facts
- EUR 20000M estimated value
- Supplies contract
- Supply of pharmaceutical products including medicines, blood derivatives, vaccines, and similar products.
- Dynamic Purchasing System (DPS) covering healthcare authorities in Campania and potentially other Italian regions.
Show full summary
This notice announces the establishment of a Dynamic Purchasing System (DPS) for the supply of pharmaceutical products (medicines, blood derivatives, vaccines, etc.) to healthcare authorities in the Campania region of Italy, with potential extension to other Italian regions. The DPS is managed by So.Re.Sa. S.p.A., the regional purchasing body. The procedure is restricted, and the estimated total value is €20 billion. The deadline for submission of initial tenders is 6 December 2028.
Risks
Only the notice and XML data are available; full procurement documents (specifications, contract terms, qualification c...
The high estimated value (€20 billion) is likely to attract many bidders, including large pharmaceutical companies, mak...
Restricted procedure — pre-qualification required
No procurement documents available
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Administrative
- Submission of tenders via the DPS platform (www.soresa.it).
- Tenders must be submitted in Italian.
- All lots (categories) must be covered in a single submission.
Requirements may be incomplete.
Buyer
Location
Naples, ITA
Website
Buyer profile
Identifier
7691971
Activity
General public services
Procurement Details
- Publication date
- 08 Dec 2022
- Languages
- Italian
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 687775-2022
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
70 / 100
Complexity
65 / 100
Risk factors
Only the notice and XML data are available; full procurement documents (specifications, contract terms, qualification c...
The high estimated value (€20 billion) is likely to attract many bidders, including large pharmaceutical companies, mak...
Restricted procedure — pre-qualification required
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications